A Phase 1a/1b Randomized Double-blind Placebo-controlled Single and Multiple Ascending Dose Study of EDP1066 in Healthy Participants and Participants With Mild to Moderate Psoriasis and Atopic Dermatitis
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Dec 2019
Price : $35 *
At a glance
- Drugs EDP 1066 (Primary)
- Indications Atopic dermatitis; Psoriasis
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Evelo Biosciences
- 03 Dec 2019 Planned number of patients changed from 96 to 168.
- 03 Dec 2019 Planned End Date changed from 30 Jun 2019 to 30 Mar 2020.
- 03 Dec 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Dec 2019.